Clinical trial
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
NCT01281254 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT01281254 |
|---|---|
| Title | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) |
| Official title | A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | AMG386 plus PLD, Placebo plus PLD |
| Enrollment | 223 |
| Start date | Apr 18, 2011 |
| Primary completion | Aug 29, 2014 |
| Completion | Apr 19, 2017 |
| First posted | Jan 21, 2011 |
| Last update posted | Dec 2, 2017 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, New Zealand, Poland and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: